This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage progression in patients with active psoriatic arthritis.

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic ...

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients with no new safety concerns.

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have ...

Johnson & Johnson (NYSE: JNJ) announced today that its drug TREMFYA (guselkumab) has met the primary and major secondary endpoints in a Phase 3b APEX study for treating active psoriatic arthritis ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...

HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), ...

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: JNJ) announced today that its drug TREMFYA (guselkumab) has met the primary and major secondary endpoints in a Phase 3b APEX study for treating active ...